Innovent Biologics, Inc. (OTCMKTS:IVBXF – Get Free Report) was the recipient of a significant decrease in short interest in June. As of June 30th, there was short interest totaling 22,285 shares, a decrease of 97.9% from the June 15th total of 1,073,474 shares. Based on an average daily volume of 3,128 shares, the short-interest ratio is currently 7.1 days.
Innovent Biologics Trading Up 0.4%
IVBXF traded up $0.05 during mid-day trading on Friday, hitting $11.39. The stock had a trading volume of 1,162 shares, compared to its average volume of 4,527. Innovent Biologics has a 1-year low of $9.10 and a 1-year high of $15.12. The stock’s fifty day simple moving average is $10.36 and its 200-day simple moving average is $10.60.
Innovent Biologics Company Profile
Innovent Biologics is a China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of high-quality biologic therapies. Founded in 2011 and headquartered in the Suzhou National Biotech R&D Park, the company specializes in innovative treatments across oncology, metabolic and ophthalmology indications. Innovent’s integrated model encompasses end-to-end capabilities, from early discovery and clinical development to large-scale manufacturing and market launch.
The company has built a diversified product portfolio that includes the anti-PD-1 monoclonal antibody sintilimab (Tyvyt), approved for lymphoma and non-small cell lung cancer in China, as well as multiple biosimilars such as IBI305 (a bevacizumab biosimilar) and IBI306 (an etanercept biosimilar).
Featured Articles
- Five stocks we like better than Innovent Biologics
- AeroVironment Flies Under Wall Street’s Radar Toward a $4 Billion Target
- Micron’s $250 Billion Bet Could Reshape the AI Memory Race
- Rocket Lab’s Stock Drop Comes With a Bullish Twist
- Amazon’s New Debt Deal Puts Its AI Spending Story on Trial
Receive News & Ratings for Innovent Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innovent Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
